Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-06-07

Clinical Trial Update: Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

View source ↗

Summary

A completed UK study (P05269) evaluated the combination of ViraferonPeg and Rebetol in hepatitis C genotype 1 patients, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rebetol (ribavirin)
  • ViraferonPeg (Pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Status: COMPLETED | Results posted: 2010-06-07